What is biological computing, and what role will it play when looking to the sustainable technology of the future?
Author profile
Dr Matthew Armean-Jones
Principal Scientist in Biotechnology and Bioinnovation
Matthew Jones is a Principal Synthetic Biologist at Cambridge Consultants delivering projects for clients working at the interface between biotechnology and engineering.
Matthew is also supporting the development of our internal capabilities in cell free biology, laboratory automation and design of experiment approaches.
My insights
Can cell therapy become cheaper and easier?
Cell and gene therapy is hailed as the future of 21st century medicine but is currently too expensive to be widely used. As a principal scientist in synthetic biology, Matthew Jones is part of a team addressing this issue in an ambitious project with exciting potential.
Real-time contamination detection for cell therapy manufacture
This whitepaper goes behind the scenes of a significant breakthrough for contamination detection in cell therapy monitoring. It tells the story of PureSentry, a prototype device for on-line, real-time detection.